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Summary Background. The current European baseline series consists of 30 allergens, and was
last updated in 2015.
Objectives. To use data from the European Surveillance System on Contact Allergies
(ESSCA) to propose an extension to the European baseline series in response to changes
in environmental exposures.
Methods. Data from departmental and national extensions to the baseline series,
together with some temporary additions from departments contributing to the ESSCA,
were collated during 2013–2014.
Results. In total, 31689 patients were patch tested in 46 European departments. Many
departments and national groups already consider the current European baseline series
to be a suboptimal screen, and use their own extensions to it. The haptens tested
are heterogeneous, although there are some consistent themes. Potential haptens to
include in an extension to the European baseline series comprise sodium metabisulfite,
formaldehyde-releasing preservatives, additional markers of fragrance allergy, propolis,
Compositae mix, and 2-hydroxyethyl methacrylate.
Conclusion. In combinationwith other published work from the ESSCA, changes to the
current European baseline series are proposed for discussion. As well as addition of the
allergens listed above, it is suggested that primin and clioquinol should be deleted from
the series, owing to reduced environmental exposure.
Key words: Compositae mix; European baseline series; formaldehyde releaser;
fragrance; 2-hydroxyethyl methacrylate; propolis; sodiummetabisulfite.
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The allergens used in any baseline series constitute an
empirical choice reflecting a variety of factors, not least
the exposures of the local population. Considerations in
choosing substances to test have been reviewed (1), and
have guided subsequent revisions of the European base-
line series (EBS), most recently in 2015 (2). In practice,
revisions have been proposed and implemented by the
European Environmental Contact Dermatitis Research
Group (3) on behalf of the ESCD (www.escd.org).
The contents of a generally recommended baseline
series such as the EBS should be based on a sufficiently
broad and valid evidence base. Another function of a
baseline series should be to include extensions for adap-
tation to changes in environmental exposures at a local,
regional or national level. Those extensions that prove
useful for most investigators will provide incontrovertible
evidence to support their inclusion into a core baseline
series. The aim of this article is to stimulate debate on
the current allergens included in the EBS, with the aim of
creating amore open and responsive process for updating
the series, using data provided by the European Surveil-
lance System on Contact Allergies (ESSCA) to generate
initial discussion.
Method
The ESSCA network has already been described in pre-
vious publications (4). Briefly, clinical and demographic
data, along with patch test results of the baseline series
used in the departments, of all patients patch tested in
the departments participating in the ESSCA are docu-
mented electronically in the local departments, by the use
of diverse data capture software and partly the multilin-
gual softwareWINALLDAT/ESSCA provided by the ESSCA (5).
Anonymized data are pooled in the ESSCA data centre in
Erlangen for further analysis (6) with R (version 3.3.2;
www.R-project.org) software (7). Data from departmen-
tal and national extensions to the baseline series, together
with some temporary additions, are also collated, pro-
vided that they have been tested in strictly consecutive
patients to achieve comparability. These additional data
may give an impression of the value of the respective aller-
gens for future inclusion.
The study period was January 2013 to December
2014. The study included 12 European countries and,
in total, 46 departments that contributed data on the
EBS, with or without extensions and omissions. The
present analysis is focused explicitly on allergens that
were not part of the EBS that was valid at the time (8), but
that have, however, been included in departmental and,
preferably, national extensions to it, tested in consecutive
patients. Hence, the present analysis is based on a subset
of participating departments (see Acknowledgements),
as some departments contributed only EBS data.
Altogether, 31 689 patients were registered who had
been testedwith the EBS (with orwithout additions), with
readings at least between day (D) 3 and D5. TRUE Test®
employing ahydrocellulosematrix for thehaptens instead
of pet. or water had been used in a relatively small num-
ber of patients (n=1214), the vast majority of patients
having been tested with pet.-based and water-based hap-
tens, and investigator-loaded chamber systems.Moreover,
twoGermandepartments use a1-day patch test exposure,
applied to 948 patients.
Results
In the years 2013 and 2014, 31689 patients were patch
tested in the 46 European departments. The character-
istics of this clinical population and patch test results
obtained with the EBS have been published previously
(9). As the Danish and Slovenian and a few other single
department(s) shared data on results obtained with the
EBS ‘as is’, they did not contribute to the present anal-
ysis. The frequencies of doubtful reactions, irritant reac-
tions and different grades of positive reaction are shown
in Table 1a–k for those allergens that were tested inmore
than one department.
Moreover, the following allergens were tested in con-
secutive patients in single departments, and yielded the
following results; this includes allergens that had been
tested in different concentrations in other departments
and are shown in Table 1:
• Imidazolidinyl urea 1% pet. [Italy-11]: 1217
patients tested; one + reaction (0.1% positive).
• Bronopol (2-bromo-2-nitropropane-1,3-diol) 0.3%
pet. (UK-99): 2503 patients tested; 2 ?+ reactions
and 16 + reactions (0.6% positive).
Results obtained with allergens that were not part of
the EBS obtained with TRUE Test® are shown in Table 2.
Note that TRUE Test® had been used in <20 patients
in Basel (Switzerland) and Amsterdam VU (The Nether-
lands); these results have been omitted, as selective testing
cannot be excluded. Therefore, the results are restricted
to the three Spanish departments and Groningen, The
Netherlands.
Discussion
The results show that many departments and national
groups already consider the current EBS to be a subopti-
mal screen, and use their own extensions to it. The hap-
tens tested are, however, heterogeneous, although there
are someconsistent themes. Inaddition tobeing common,
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
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Table 1. Pattern of reaction to allergens beyond the European baseline series valid during the study period tested in consecutive patients
in more than one department of the European Surveillance System on Contact Allergies network. Allergens in pet., except where indicated
otherwise
Department/country n tested % ?+/IR % + % ++/+++ % positive % stand. positive 95%CI
(a) Sodium metabisulﬁte 1%
UK 5969 0.2 1.4 1.5 2.9 2.9 2.4–3.3
NL-02 1969 1.3 4.6 0.4 5.0 4.9 3.9–5.8
PL-01 200 0 0.5 1.0 1.5 1.6 0–3.5
(b) Diazolidinyl urea 2%
ES 1190 0 0.2 0.4 0.6 0.6 0.1–1.0
NL 2568 0.4 0.9 0 0.9 0.9 0.5–1.3
UK 6592 0.1 0.2 0.4 0.6 0.6 0.4–0.8
DE-01 282 2.1 0.7 0 0.7 1.0 0–2.5
IT-11 1217 0 0 0.1 0.1 0.1 0–0.2
LT-01 256 0 0 0 0 0 0–1.2
PL-01 203 0 0 0.5 0.5 0.6 0–1.7
(c) Imidazolidinyl urea 2%
ES 1190 0 0.2 0.4 0.6 0.6 0.1–1.0
NL 2568 0.4 0.5 0.1 0.5 0.6 0.3–0.8
UK 5903 0.1 0.1 0.1 0.2 0.2 0.1–0.3
DE-01 283 0.7 0.4 0 0.4 0.7 0–2.2
FI-01 231 0.4 0 0.4 0.4 0.3 0–0.8
IT-02 576 0.2 0.7 0 0.7 0.6 0–1.3
LT-01 256 0 0 0 0 0 0–1.2
PL-01 203 0 0 0.5 0.5 0.6 0–1.7
(d) 2-Bromo-2–nitropropane-1,3-diol 0.25%
UK 3401 0.1 0.8 0.2 0.9 0.9 0.6–1.3
IT-11 1217 0 0.1 0 0.1 0.1 0–0.2
LT-01 253 0 1.2 0.4 1.6 1.4 0–2.9
(e) 2-Bromo-2–nitropropane-1,3-diol 0.5%
CH 1423 2.0 0.4 0.1 0.5 0.5 0.1–0.8
DE 1924 1.0 0.5 0.1 0.6 0.6 0.2–0.9
AT-25 292 0.3 0 0.3 0.3 0.3 0–0.8
ES-01 766 0 0.4 0.7 1.0 1.2 0.3–2.1
LT-01 3 0 0 0 0 0 0–63.2
NL-01 599 0 0 0 0 0 0–0.5
UK-08 1293 0.3 0.5 0.2 0.7 0.7 0.2–1.2
(f) Propolis 10%
CH 2675 10.8 3.1 1.2 4.4 4.1 3.3–4.9
DE 3547 8.1 2.9 0.9 3.7 3.4 2.7–4.0
PL 1816 0.8 2.0 0.8 2.8 2.9 2.1–3.6
UK 2090 0.1 0.2 0 0.3 0.3 0.1–0.5
AT-25 509 1.6 5.9 0.4 6.3 5.6 3.6–7.7
IT-02 576 0.3 0.9 1.2 2.1 2.1 0.9–3.3
LT-01 256 0 0.4 0.4 0.8 0.7 0–1.9
(g) Oil of turpentine 10%
CH 2672 1.4 0.7 0.4 1.1 1.0 0.6–1.3
DE 3555 1.8 1.1 0.3 1.3 1.1 0.8–1.5
AT-25 509 0.4 2.0 0.2 2.2 1.7 0.7–2.7
(h) Compositae mix 2.5%
UK 3464 0 0.6 0.5 1.1 1 0.7–1.4
FI-01 232 0 0 0 0 0 0–1.3
(i) Compositae mix 5%
CH 2698 1.1 0.7 0.5 1.2 1 0.7–1.4
DE 3590 1.5 1.0 1.1 2.1 2.0 1.5–2.5
AT-25 510 0.4 2.9 0.2 3.1 2.9 1.3–4.4
IT-01 4 0 0 0 0 0 0–52.7
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
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Table 1. Continued
Department/country n tested % ?+/IR % + % ++/+++ % positive % stand. positive 95%CI
(j) Compositae mix 6%
IT 951 0.4 0.2 0.1 0.3 0.2 0–0.5
(k) Caine mix III 10%
UK 7197 0.3 0.4 0.4 0.9 0.8 0.6–1.1
FI-01 231 2.2 0.4 0.4 0.9 1 0–2.4
PL-02 1613 0.5 2.1 0.4 2.5 2.7 1.9–3.6
(l) Carba mix 3%
ES 1723 0.1 0.8 1.1 2.0 2.0 1.3–2.7
IT 1737 2.1 3.6 0.5 4.0 4.2 3.3–5.2
NL-02 1969 4.8 7.8 0.5 8.2 8.2 7.0–9.5
UK 7197 0.3 1.0 0 1.0 1.0 0.8–1.2
AT, Austria; CH, Switzerland; CI, confidence interval; DE, Germany; ES, Spain; FI, Finland; IR, irritant reaction; IT, Italy; LT, Lithuania; NL, The
Netherlands; PL, Poland; UK, United Kingdom; Stand., standardized for age and sex.
Table 2. Patch test results obtainedwith the allergens fromTRUE Test® that are not part of the European baseline series valid during the study
period. The maximum reading between day (D) 3 and D5 (inclusive) was considered
Department/country n tested % ?+/IR % + % ++/+++ % positive % stand. positive 95%CI
(a) Diazolidinyl urea
ES 570 0 0.7 0 0.7 1.0 0–2.0
NL-01 599 0.3 0.3 0 0.3 0.3 0–0.8
(b) Imidazolidinyl urea
ES 570 0.2 0.4 0 0.4 0.5 0–1.2
NL-01 599 0.8 0.2 0 0.2 0.2 0–0.5
(c) Quinoline mix
ES 570 0 0.4 0 0.4 0.3 0–0.6
(d) Ethylenediamine HCl
ES 570 0 0.2 0.7 0.9 1.0 0–1.9
NL-01 599 1.3 0.5 0.2 0.7 0.6 0–1.2
(e) Thiomersal
ES 570 0 1.8 4.7 6.5 7.8 5.2–10.4
NL-01 599 0.5 0.3 0.3 0.7 0.6 0–1.3
(f) Caine mix
ES 570 0 0.2 2.3 2.5 2.2 1.0–3.4
NL-01 599 0.5 0.8 0.2 1.0 0.9 0.2–1.6
(g) Hydrocortisone 17-butyrate
ES 570 0 0.2 0 0.2 0.1 0–0.4
NL-01 599 2.3 0.3 0 0.3 0.3 0–0.7
(h) Carba mix
ES 570 0.4 1.4 0.5 1.9 2.6 1.0–4.2
NL-01 599 2.2 2.7 1.0 3.7 3.3 1.9–4.6
CI, confidence interval; ES, Spain; IR, irritant reaction; NL, The Netherlands; Stand., standardized for age and sex.
screening haptens need to be relevant, and an assessment
of this in one centre is shown in Table 3. The article of
Bruze et al. (1) recommends inclusion when the contact
allergy prevalence is 0.5–1% and above.
Allergens to add
Sodium metabisulfite 1% pet. was tested in the baseline
series of three countries, with a percentage of positive
reactions (Table 1) potentially justifying inclusion in
the baseline series. There appears to be agreement that
a 1% concentration is the most sensitive (10) and is a
marker of allergy to other sulfites (11, 12). Although
relevance can be hard to establish (13), the frequency
of reactions is such that inclusion in the baseline series
should be considered, with this preservative being widely
used in cosmetic products, medicaments, industry,
and food.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
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Table 3. Proposed changes to the baseline series with results of testingwith the baseline series of one UK centre during 2016 in 1019 patients.
Additional haptens in bold have a prevalence that is insufficient to warrant further inclusion. All allergens in pet.
% Positive 95%CI % CR % PR/NR
Hapten to add (based on our data)
Sodium metabisulﬁte 1% 2.9 1.9–4.1 1.8 1.1
2-Bromo-2-nitropropane-1,3-diol (Bronopol) 0.5% 0.39 0.11–1.0 0.29 0.10
Diazolidinyl urea 2% 0.79 0.34–1.5 0.69 0.10
Imidazolidinyl urea 2% 0.39 0.11–1.0 0.39 0
Propolis 10% 1.3 0.68–2.2 1.2 0.10
Compositae mix 5% or 6% 0.49a,b 0.16–1.1 0.29 0.20
Carba mix 3% 0.98 0.47–1.8 0.69 0.30
1,3-Diphenylguanidine 1% 0.1 0–0.55 0.10 0
Hapten to add (based on the literature)
2-Hydroxyethyl methacrylate 2% 1.4 0.75–2.3 0.98 0.39
Linalool hydroperoxide 1% 4.7 3.49–6.2 4.2 0.49
Limonene hydroperoxide 0.3% 4.3 3.15–5.8 3.9 0.39
Melaleuca alternifolia 5% 0.29 0.06–0.86 0.29 0
Mentha piperita 2% 0.22 0.02–0.71 0.20 0
Santalum album 2% 0.59 0.22–1.3 0.49 0.1
Hapten to switch
Caine mix III 10% 0.39 0.11–1.0 0.2 0.1
Black rubber mix 0.6% NT – – –
Hapten to delete
Clioquinol 5% 0.1c 0–0.55 0.1 0
Primin 0.01% NT – – –
aCompositae mix tested at 2.5%.
bSesquiterpene lactone mix 0.1% pet. gave 0.29% positive reactions by comparison.
cQuinoline mix 6% pet. tested.
CI, confidence interval; CR, current relevance; NR, not relevant; NT, not tested; PR, past relevance.
Formaldehyde releasers: diazolidinyl urea, imidazo-
lidinyl urea and Bronopol (2-bromo-2-nitropropane-1,
3-diol) are already added to an extended baseline series
in many countries (Table 1). The frequency of posi-
tive reactions would appear to justify inclusion. These
formaldehyde-releasing preservatives are commonly not
suspected clinically, and have been included in national
baseline series in several countries (14, 15).
Fragrance(s) are currently screenedwithin the baseline
series, but there is a recognition that the current screen
is inadequate. Individual groups have taken varying
approaches, including testing of multiple individual
fragrance allergens, namely, those 26 fragrances that
currently need to be labelled according to the Cosmet-
ics Regulation (16), testing with oxidized allergens,
especially those of limonene and linalool (17), and
using essential oils (18). It seems likely that testing
with limonene hydroperoxide 0.3% pet. and linalool
hydroperoxide 1% pet. (19) together with oils ofMelaleuca
alternifolia, Mentha piperita and Santalum album (20)
(which contain allergens predominantly other than
those in the baseline series plus limonene and linalool)
might be a way of maximizing yield while minimizing
the number of additional allergens tested. However, the
irritancy of hydroperoxides is an issue at the concentra-
tions mentioned. A recent study testing routinely with
all 26 allergens that require labelling showed that, in
addition to linalool and limonene hydroperoxides, Ever-
nia furfuracea yielded a significant number of additional
relevant reactions (21). The routine testing of the 26
substances that currently need to be labelled – with
limonene and linalool in their oxidized forms – or at least
of those of these haptens that have proven to be important
in terms of frequency of sensitization can be viewed as a
useful strategy. From a practical perspective, both previ-
ous exposure and, thus, relevance can be verified, and
future avoidance can bemanaged, thanks to the labelling.
Although we may not yet have identified an ideal combi-
nation, given the high frequency of false-negative results
for fragrance allergy when only the current screen-
ing fragrance mixes are used, it seems essential to add
additional fragrance allergens to an extended baseline
series.
Propolis 10% pet. was tested in seven countries
(Table 1), with, apart from the United Kingdom, a
frequency of reactions justifying inclusion. Notwith-
standing the current low prevalence of positives in the
United Kingdom, in the past propolis has been included
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
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in the British baseline series (22), when the prevalence of
allergy was 1.9% among those tested. Patients who are
allergic to propolis frequently co-react with colophonium
and fragrances (23), and, given the current popularity of
‘natural’ products and its widespread use (24), it would
seem that more extensive testing throughout Europemay
be justified.
Compositae mix 5/6% pet. has been recognized as being
a useful supplement to sesquiterpene lactone mix 0.1%
pet. for detection of allergy to members of the Com-
positae/Asteraceae family of plants (25, 26). Although
some have found that the additional yield over and above
sesquiterpene lactone mix alone is insufficient to war-
rant additional testing in a baseline series in Sweden
(27), the notion remains that sesquiterpene lactone mix
alone is an inadequate screen (28, 29), warranting fur-
ther study. The commercial allergen tested at 5% has also
been shown to be sensitizing (30), with equal numbers of
patients being sensitized and additional allergic patients
detected. This is not a property desirable for any screening
allergen. In the United Kingdom, a lower concentration
of Compositae mix II, that is, 2.5% pet. (Chemotechnique
Diagnostics, Vellinge, Sweden), has been included in the
baseline series for many years, without evidence of active
sensitization, but continued sensitivity in the detection of
Compositae allergy (Table 3).
1,3-Diphenylguanidine 1% pet. is a rubber acceler-
ator contained within the ‘carba mix’, although it is
not a dithiocarbamate. Recent studies of rubber allergy
from the ESSCA (31) and EPIDERM (32) suggest that
carba mix is causing more frequent allergic reactions,
although concerns have been raised about the irritancy
of the patch test preparation. Many manufacturers of
gloves have switched from thiuram to carbamates as
accelerators, raising the possibility that carbamates, as
a consequence of increased exposure, may be sensitizing
more frequently. However, thiuram mix is thought to be
an adequate screen for carbamate allergy (33), as both
exist as a redox pair in equilibrium in vivo, with thiuram
mix being the better marker of contact allergy (34).
Consequently, it is thought that 1,3-diphenylguanidine
may be responsible for the increasing prevalence of
reactions to the carba mix. Although there is no defini-
tive answer, consideration should be given to testing
more widely with zinc diethyldithiocarbamate 1% pet.
and 1,3-diphenylguanidine to avoid false-negative reac-
tions. However, given the low yield from testing with
1,3-diphenylguanidine alone (Table 3), it may be better
to restrict this to a rubber series (35) and patients with
hand dermatitis.
2-Hydroxyethyl methacrylate (2-HEMA) 2% pet.
has previously been used as a marker of contact
allergy to methacrylates (36). Traditionally, expo-
sure was occupational, but the recent fashion for
acrylate-containing nail products is resulting in increases
in the numbers of cases of non-occupational hand and
facial dermatitis (37, 38). Although data on systematic
testing in the current environment do not exist, it seems
probable that consideration needs to be given to eval-
uating more extensive testing with acrylates to avoid
missing what is becoming an increasingly common con-
tact allergen in a domestic setting. In the previous study
from 2008 (14), 63% of sensitized patients would have
been missed if acrylates had not been tested routinely.
Sensitization is also a concern when acrylates are tested
(39). The high frequency of sensitization reported was
attributable to various acrylates, that is, ethyl acrylate,
2-hydroxy ethyl acrylate, etc., and not to methacrylates
such as 2-HEMA. After testing of >1000 patients with
2-HEMA in a baseline series, no cases of active sensitiza-
tion became apparent (Table 3), even though patients are
encouraged to return if they develop late reactions. As
users of acrylate nails are predominantly female, another
way to reduce exposure and sensitization risk would be to
create a sex-specific baseline series.
Allergens to switch
Caine mix III 10% pet. This mix, containing benzocaine,
cinchocaine (dibucaine), and tetracaine, the latter two as
hydrochlorides, has long been used instead of benzocaine
5% pet. in the baseline series in the United Kingdom (40,
41). Data from the ESSCA, as they do not provide a direct
comparison, are unable to confirm that more widespread
use of cainemix III across Europe would be beneficial, but
do suggest that instituting amorewidespread comparison
would be of value. In general, those centres of the ESSCA
testing caine mix III had a higher yield of positive results
than obtained with benzocaine 5% pet. (8) during the
same time period. Lidocaine (lignocaine) is an amide local
anaesthetic that does not cross-react. However, there are
increasing reports of contact allergy; in one study, when
lidocainewas included in amedicament series, therewere
more cases of contact allergy to lidocaine than to other
topical anaesthetic agents (42). This suggests that the
usefulness of including lidocaine as a screening agent
should be evaluated.
Black rubber mix 0.6% pet. may prove a better
screen for rubber antioxidants than N-isopropyl-
N′-phenyl-p-phenylenediamine (IPPD) 0.1% pet. (31)
alone. A prospective comparison may help to provide
evidence of the superiority of one above the other, ide-
ally based on thorough relevance assessment and/or
breakdown testing of mix constituents.
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Allergens to omit
Testing with the baseline series in departments of the
ESSCA during 2013–2014 suggests that two allergens
in particular should be considered for removal from
the EBS.
Primin 0.01% pet., with an age- and sex-standardized
prevalence of allergy of 0.2% (95%CI: 0.2–0.3%), no
longer appears to warrant inclusion. The development of
hypoallergenic varieties of Primula obconica and the sub-
sequent reduction in the frequency of contact allergy to
the plant is well documented (43). However, patch test-
ing may still be relevant in subgroups of the population
(e.g. retirees and household workers in Italy) (44), and
addition to a plant series may be a better option for more
selected testing.
Clioquinol 5% pet., with an age- and sex-standardized
prevalence of allergy of 0.3% (95%CI: 0.2–0.4%), also
appears to yield insufficient allergic reactions to warrant
continued inclusion. This probably reflects changing pre-
scribing habits and an aversion to the yellow staining of
this topical antiseptic, exposure to which may quite eas-
ily be identified by proper history-taking, enabling aimed
testing as indicated.
Conclusion
It is hoped that the above discussion has highlighted some
areas for further investigation. We propose that a (tem-
porary) (45) supplement to the baseline series (Table 3)
might prove to be a useful way of evaluating the need
to test more widely, and prove to be a practical way of
beingmore responsive to changes in environmental aller-
gen exposure while further information is gathered.
It is inevitable that there will be regional and national
differences requiring additions to the above, depending on
local exposures, that national societies will continue to
recommend: for instance, ethylenediamine dihydrochlo-
ride remaining in the Spanish baseline series (46).
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